Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age

• Published in: Human vaccines & immunotherapeutics Vol. 10; no. 10; pp. 2795 - 2798
• Main Authors: Silfverdal, Sven A, Assudani, Deepak, Kuriyakose, Sherine, Van Der Meeren, Olivier
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 2014
• Subjects: anti-hepatitis B surface antigen; Antibodies, Bacterial - blood; Antibodies, Bacterial - immunology; Antibody Formation; antibody persistence; booster; Bordetella pertussis - immunology; Child, Preschool; Clostridium tetani - immunology; confidence interval; Corynebacterium diphtheriae - immunology; Diphtheria - immunology; Diphtheria - prevention & control; diphtheria-tetanus-acellular pertussis; diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b vaccine; Diphtheria-Tetanus-Pertussis Vaccine - immunology; DTPa-HBV-IPV; DTPa-IPV; FHA; filamentous haemagglutinin; geometric mean antibody concentration; GMC; Haemophilus Infections - immunology; Haemophilus Infections - prevention & control; Haemophilus influenzae type b; Haemophilus influenzae type b - immunology; Haemophilus Vaccines - immunology; HBs; hepatitis B; Hepatitis B - immunology; Hepatitis B - prevention & control; Hepatitis B Antibodies - blood; Hepatitis B Vaccines - immunology; Hib; Humans; Immunization Schedule; Immunization, Secondary; inactivated poliovirus and Haemophilus influenzae type b vaccine; micrograms per milliliter; not applicable; pertactin; pertussis toxin; Poliomyelitis - immunology; Poliomyelitis - prevention & control; Poliovirus Vaccine, Inactivated - immunology; polyribosylribitol phosphate; PRN; PRP; Research Paper; Tetanus - immunology; Tetanus - prevention & control; Vaccination; vaccination schedule; vaccine; Vaccines, Combined - immunology; Whooping Cough - immunology; Whooping Cough - prevention & control; CI, confidence interval; HBs, anti-hepatitis B surface antigen; vaccination schedule; NA, not applicable; PRN, pertactin; DTPa-HBV-IPV/Hib, - diphtheria-tetanus-acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine; PT, pertussis toxin; booster; vaccine; PRP, polyribosylribitol phosphate; DTPa-IPV/Hib, diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b vaccine; antibody persistence; Hib, Haemophilus influenzae type b; μg/ml, micrograms per milliliter; FHA, filamentous haemagglutinin; GMC, geometric mean antibody concentration
• ISSN: 2164-5515; 2164-554X; 2164-554X
• DOI: 10.4161/21645515.2014.970494

The combined diphtheria-tetanus-acellular pertussis-hepatitis B-poliomyelitis/Haemophilus influenza vaccine (DTPa-HBV-IPV/Hib: Infanrix™ hexa, GlaxoSmithKline Vaccines) is used for primary vaccination of infants in a range of schedules world-wide. Antibody persistence after 4 DTPa-HBV-IPV/Hib doses in the first 2 y of life has been documented, but long-term persistence data following the 3, 5, 11-12 months (3-5-11) infant vaccination schedule, employed for example in Nordic countries, are limited. We assessed antibody persistence in 57 5-year-old children who had received either DTPa-HBV-IPV/Hib or DTPa-IPV/Hib (Infanrix™-IPV/Hib, GlaxoSmithKline Vaccines) in the 3-5-11 schedule. Among DTPa-HBV-IPV/Hib recipients, 7/12 retained seroprotective antibody concentrations for diphtheria, 10/12 for tetanus, 5/12 for hepatitis and 10/12 for Hib. Detectable antibodies were observed for 0/12 children for pertussis toxin (PT), 12/12 for filamentous haemagglutinin (FHA) and 8/12 for pertactin (PRN). Among DTPa-IPV/Hib recipients, 28/45 retained seroprotective anti-diphtheria concentrations, 34/44 for tetanus and 40/45 for Hib. Detectable antibodies were observed for 9/45 children for PT, 41/45 for FHA and 34/45 for PRN. Antibody persistence in DTPa-HBV-IPV/Hib and DTPa-IPV/Hib-vaccinees appeared similar in 5 y olds to that previously observed in children of a similar age who had received 4 prior doses of DTPa-HBV-IPV/Hib (or DTPa-IPV/Hib). As in subjects primed with 4 prior doses, we observed that antibodies markedly declined by 5 y of age, calling for the administration of a pre-school booster dose in order to ensure continued protection against pertussis.